Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 10/20 | 0.38 |
| ▸ | BACE1 | P56817 | 10/20 | 0.38 |
| ▸ | BCHE | P06276 | 7/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597032 | 0.89 | GRIN2B (0.41) | MEN1KMT2ARIPK2ACHEBACE1 | |
| SCHEMBL5596731 | 0.87 | GRIN2B (0.41) | MEN1KMT2ARIPK2ACHEBACE1 | |
| SCHEMBL5412407 | 0.86 | GRIN2B (0.40) | MEN1KMT2ARIPK2ACHEBACE1 | |
| SCHEMBL5412409 | 0.86 | GRIN2B (0.40) | MEN1KMT2ARIPK2ACHEBACE1 | |
| SCHEMBL5596945 | 0.83 | MEN1 (0.44) | MEN1KMT2ARIPK2POLBALDH1A1 | |
| SCHEMBL5596442 | 0.82 | MEN1 (0.42) | MEN1KMT2ARIPK2 | |
| SCHEMBL5596498 | 0.81 | OPRM1 (0.34) | RIPK2 | |
| SCHEMBL5596704 | 0.81 | MEN1 (0.40) | MEN1KMT2ARIPK2POLBALDH1A1 | |
| SCHEMBL5596476 | 0.79 | SCN9A (0.37) | KMT2ADRD2POLBALDH1A1 | |
| SCHEMBL5419726 | 0.79 | GRIN2B (0.42) | MEN1KMT2ADRD2ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | MEN1 2341/4885KMT2A 2386/4885RIPK2 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.